On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity. The results showed that the cohort ...

When its arrival was announced in 1726, the Evening Post heralded it as 'an immediate best-seller'. The publisher, Benjamin Motte, was kept busy with the production of two more editions.